Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8 + T cells.
Kathryn M LaPorteRosmely HernandezAlicia Santos SavioThomas R MalekPublished in: Journal for immunotherapy of cancer (2023)
Targeting the high-affinity IL-2R on tumor-specific T cells with HD mIL-2/CD25 alone or with PD-1 blockade supports antitumor responses, where the resulting memory response may afford long-term protection against tumor re-emergence.